Jeremy S. Abramson
A5002103749- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- CNS Lymphoma Diagnosis and Treatment
- Biosimilars and Bioanalytical Methods
- Lung Cancer Treatments and Mutations
- Immunodeficiency and Autoimmune Disorders
- Protein Degradation and Inhibitors
- Cancer Genomics and Diagnostics
- Acute Lymphoblastic Leukemia research
- Integrated Circuits and Semiconductor Failure Analysis
- Cutaneous lymphoproliferative disorders research
- Viral Infectious Diseases and Gene Expression in Insects
- Virus-based gene therapy research
- Immune Cell Function and Interaction
- Monoclonal and Polyclonal Antibodies Research
- Chronic Myeloid Leukemia Treatments
- T-cell and Retrovirus Studies
- Cancer-related gene regulation
- Chromatin Remodeling and Cancer
- Cancer Immunotherapy and Biomarkers
- Multiple Myeloma Research and Treatments
- Glioma Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
Massachusetts General Hospital
2016-2025
Harvard University
2016-2025
Hôpital 20 Août
2023
National Tsing Hua University
2023
Institutul Oncologic din Republica Moldova
2023
Mansoura University
2023
Institut Català d'Oncologia
2023
Universitat de Barcelona
2023
Institut d'Investigació Biomédica de Bellvitge
2023
Bhaktapur Cancer Hospital
2023
Ibrutinib has been approved by the Food and Drug Administration for treatment of patients with untreated chronic lymphocytic leukemia (CLL) since 2016 but not compared chemoimmunotherapy. We conducted a phase 3 trial to evaluate efficacy ibrutinib, either alone or in combination rituximab, relative
B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements, also known as “double-hit” (DHL), are rare neoplasms characterized by highly aggressive clinical behavior, complex karyotypes, a spectrum of pathologic features overlapping Burkitt lymphoma (BL), diffuse large (DLBCL) B-lymphoblastic lymphoma/leukemia (B-LBL). The this entity, including comparison to other high-grade neoplasms, has not been well defined. We conducted retrospective analysis 20 cases DHL seen at our institution...
Alliance/CALGB 50303 (NCT00118209), an intergroup, phase III study, compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) with standard rituximab, prednisone (R-CHOP) as frontline therapy for diffuse large B-cell lymphoma.Patients received six cycles of DA-EPOCH-R or R-CHOP. The primary objective was progression-free survival (PFS); secondary clinical objectives included response rate, overall (OS), safety.Between 2005 2013, 524...
Classical Hodgkin lymphomas (cHLs) contain small numbers of neoplastic Reed-Sternberg (RS) cells within an extensive inflammatory infiltrate that includes abundant T helper (Th)-2 and regulatory (Treg) cells. The skewed nature the cell lack effective host antitumor immune response suggest RS use potent mechanisms to evade attack. In a screen for cell-inhibitory molecules in cHL, we found selectively overexpressed immunoregulatory glycan-binding protein, galectin-1 (Gal1), through...
Axicabtagene ciloleucel (axi-cel) was approved by the Food and Drug Administration for relapsed aggressive B-cell non-Hodgkin lymphoma in part on basis of durable remission rates approximately 40% a clinical trial population. Whether this efficacy, toxicity, would be consistent postcommercial setting, with relaxed eligibility criteria bridging therapy, is unknown. This study describes efficacy safety correlates outcomes setting.
Chimeric antigen receptors redirect T cells (CAR-T) to target cancer cells. There are limited data characterizing cardiac toxicity and cardiovascular (CV) events among adults treated with CAR-T. The purpose of this study was evaluate the possible toxicities registry included 137 patients who received Covariates occurrence grade cytokine release syndrome (CRS) administration tocilizumab for CRS. Cardiac defined as a decrease in left ventricular ejection fraction or an increase serum troponin....
Five-year follow-up in a trial involving patients with previously untreated stage III or IV classic Hodgkin's lymphoma showed long-term progression-free survival benefits first-line therapy brentuximab vedotin, CD30-directed antibody–drug conjugate, plus doxorubicin, vinblastine, and dacarbazine (A+AVD), as compared bleomycin, (ABVD). A planned interim analysis indicated potential benefit regard to overall survival; data from median of 6 years are now available.
This global phase 3 study compared lisocabtagene maraleucel (liso-cel) with a standard of care (SOC) as second-line therapy for primary refractory or early relapsed (≤12 months) large B-cell lymphoma (LBCL). Adults eligible autologous stem cell transplantation (ASCT; N = 184) were randomly assigned in 1:1 ratio to liso-cel (100 × 106 chimeric antigen receptor-positive T cells) SOC (3 cycles platinum-based immunochemotherapy followed by high-dose chemotherapy and ASCT responders). The end...
Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of non-Hodgkin’s in adults. Histologic transformation FL to DLBCL (TFL) occurs approximately 15% patients is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results treatment relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel tisagenlecleucel) has emerged as novel option for TFL. These NCCN Guidelines...
In the last decade, a better understanding of molecular pathogenesis B-cell non-Hodgkin lymphomas has resulted in development novel targeted therapies, such as small molecule inhibitors select kinases receptor pathway, antibody-drug conjugates, and molecules that target variety proteins (eg, CD-19, EZH2, XPO-1-mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large lymphoma, also emerged treatment option R/R follicular lymphoma...
Importance Anthracyclines treat a broad range of cancers. Basic and retrospective clinical data have suggested that use atorvastatin may be associated with reduction in cardiac dysfunction due to anthracycline use. Objective To test whether is the proportion patients lymphoma receiving anthracyclines who develop dysfunction. Design, Setting, Participants Double-blind randomized trial conducted at 9 academic medical centers US Canada among 300 were scheduled receive anthracycline-based...